Aditxt's COVID-19 Test To Include Specific Antibodies To Detect Individual Immune Response; Shares Rise - Aditxt (NASDAQ:ADTX)

Aditxt Inc ADTX has announced enhancements to its AditxtScore for COVID-19 to include a high-sensitivity neutralizing antibody diagnostic.
The multi-dimensional immune response test tracks multiple combinations of antibody responses against several different antigens. The enhancement makes it possible to assess the strength of an individual's immune response to COVID-19.
The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM, and IgA isotypes, can provide an understanding of the strength and quality of each individual's immune response to COVID-19, whether through exposure and infection or vaccination.
AditxtScore for COVID-19 is available for use as a CLIA-validated laboratory-developed test. This test is not for self-diagnosis and is not cleared or approved by the FDA.
Price Action: ADTX shares are up 8.40% at $2.71 during the premarket session on the last check Monday.